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Abstract
Nonalcoholic fatty liver disease (NAFLD) is the most common form of chronic liver disease in the pediatric population.
Preliminary evidence suggests a potential therapeutic utility of probiotics for this condition. Here, we tested the potential
effect of the probiotic VSL#3 (a multistrain preparation composed of Streptococcus thermophilus and several species of
Lactobacillus and Bifidobacteria) on oxidative and inflammatory damage induced by a high-fat diet in the liver of young rats.
At weaning, young male Sprague-Dawley rats were randomly divided into 3 groups (n¼ 6) fed a standard, nonpurified diet
(Std; 5.5% of energy from fat) or a high-fat liquid diet (HFD; 71% of energy from fat). One of the HFD groups received by
gavage VSL#3 (13 3 109 bacteriakg21d21). After 4 wk, the HFD rats had greater body weight gain, fat mass, serum
aminotransferase, and liver weight than rats fed the Std diet. The HFD induced liver lipid peroxidation, tumor necrosis
factor (TNFa) production, protein S-nitrosylation, inducible nitric oxide synthase (iNOS), cyclooxygenase (COX)-2
expression, and metalloproteinase (MMP) activity. Moreover, in the HFD group, PPARa expression was less than in rats
fed the Std diet. In rats fed the HFD diet and treated with VSL#3, liver TNFa levels, MMP-2 and MMP-9 activities, and
expression of iNOS and COX-2 were significantly lower than in the HFD group. In VSL#3-treated rats, PPARa expression
was greater than in the HFD group. A modulation of the nuclear factor-kB pathway by VSL#3 was also demonstrated. Our
data suggest that VSL#3 administration could limit oxidative and inflammatory liver damage in patients with NAFLD. J.
Nutr. 139: 905–911, 2009.
Introduction
Nonalcoholic fatty liver disease (NAFLD)8 is the most common
form of chronic liver disease in the pediatric population, and
with the rapid rise in childhood obesity, there has been an increase
in the prevalence, recognition, and severity of this condition (1,2).
The disease is related to excessive accumulation of hepatic
fat and represents a spectrum of conditions ranging from fat
accumulation alone (steatosis without inflammation) to steato-
hepatitis (NASH) with macrovesicular steatosis in hepatocytes,
associated with inflammation and fibrosis. Therefore, NASH
is thought to be an intermediate stage in the progression from
steatosis to cirrhosis. The fatty acid excess is converted to tri-
glycerides and stored in the cytoplasm, predisposing the hepa-
tocytes to oxidative stress and to activation of inflammatory
pathways (3). In the last decade, the ‘‘2-hit’’ model has been
proposed for the pathogenesis of NASH (4). Liver fat accumu-
lation and insulin resistance characterize the first hit and are
responsible for the development of steatosis. The main factors
initiating the second hit are oxidative stress and subsequent lipid
peroxidation, together with the production of proinflammatory
cytokines, principally tumor necrosis factor (TNF)a (5,6), and
hormones derived from adipose tissue (7,8).
The PPAR family plays a key role in modulating hepatic
triglyceride accumulation and inflammatory processes. In par-
ticular, PPARa regulates fatty acid b-oxidation (9) and catab-
olism, preventing and decreasing hepatic fat storage (10). Loss
of its gene expression in mice results in hepatic steatosis under
conditions of increased fatty acid metabolism in liver, such as
fasting or consuming a high-fat diet (11,12).
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Probiotics have been proposed to prevent and treat different
inflammatory conditions of the gastrointestinal tract (13,14).
These therapeutic effects might be related to a variety of direct
and indirect mechanisms, including modulation of local micro-
biota, epithelial barrier function, and the immune system (15).
Because the probiotic modulatory effect on the intestinal micro-
flora could influence the gut-liver axis, these microorganisms
have also been proposed as possible adjunctive therapy in some
types of chronic liver disease (16,17). A recent meta-analysis in
adult patients suggests that probiotics could be useful in NAFLD
treatment and that further research elucidating the mechanisms
of such effects is needed (18). Preliminary data obtained in rat
models of alcoholic and nonalcoholic steatohepatitis showed
that the treatment with probiotics could be effective in limiting
liver damage (19–21), but the exact mechanism of these effects is
still largely undefined.
The aim of the present study was to test the effect of
probiotics on inflammatory and oxidative mechanisms involved
in the pathogenesis of liver damage in an experimental animal
model of NAFLD. We focused the study on the main patholog-
ical mechanisms involved in the pathogenesis of NAFLD. We
chose VSL#3, a multistrain cocktail composed of Streptococcus
thermophilus and several species of Lactobacillus and Bifido-
bacteria, that was previously used in in vitro and in vivo studies
(17,21). We used a previously established animal model that
reproduces the key features of NASH by feeding young male rats
a high-fat liquid diet (HFD) (22,23). Compared with genetically
modified mice (e.g. ob/ob), this animal model better resembles
the pathological events implicated in the pathogenesis of NAFLD
induced by a fatty diet. Here, 4 wk after treatment with probiotics
in rats receivingHFD,we investigated the modifications of several
hepatic oxidative and inflammatory parameters. We also evalu-
ated the involvement of nuclear factor-kB (NF-kB) pathway in the
probiotic effect.
Materials and Methods
Diets and drugs. The HFD was purchased from Research Diets
(product no. L10042). This liquid diet had 71% of energy derived from
fat, 11% from carbohydrates, and 18% from protein and its composi-
tion was been previously described by Lieber-DeCarli (22,23). The fat
composition of this diet was 48.5 g/L corn oil, 28.4 g/L olive oil, and
2.7 g/L safflower oil. A standard nonpurified pelleted diet (Std; Global
diet 2018), described by Guglielmi et al. (24), was purchased from
Harlan Italy, and had 15% of energy derived from fat, 22% from
protein, and 63% from carbohydrate (Table 1). The Std and HFD diets
contained 13.7 and 41.8 MJ/kg, respectively. Because the 2 diets differed
in several aspects, the nonpurified pelleted diet may have introduced
other variables not present in the HFD; therefore, the Std diet was
included for reference. The probiotic mixture, named VSL#3, is a com-
mercial probiotic product provided by Professor Claudio De Simone,
Department of Experimental Medicine, University of L’Aquila, L’Aquila,
Italy. VSL#3 contains 4 species of Lactobacilli: 3.1% (wt:wt) of
L. plantarum, 7.3% of L. acidophilus, 16% of L. casei, and 8.4% of
L. delbrueckii subsp. Bulgaricus; 3 species of Bifidobacteria: B. infantis,
B. breve, and B. longum, representing 17.7% of the mixture; and 47.5%
of Streptococcus salivarius subsp. Thermophilus.
Rat model. After weaning, young male Sprague-Dawley rats (113.0 6
2.5 g; Charles River Laboratories) were randomly divided into 3 groups
(n ¼ 6 rats each group) as following: 1) a control group, receiving a Std
diet; 2) a HFD diet-fed group; and 3) HFD rats treated by gavage with
VSL#3 (HFD1VSL#3; 133 109 bacteriakg21d21). HFD and Std diet-fed
rats were gavaged with water as vehicle.
It has been previously shown that the rats receiving HFD developed
the pathologic changes of NASH (23). To explore the preventive effects
of probiotics, VSL#3 was administered by gavage to 1 group of rats fed
the HFD for 4 wk. All animal procedures were carried out in accordance
with the Institutional Guidelines and complied with the Italian D.L.
no.116 of January 27, 1992 of Ministero della Salute and associated
guidelines in the European Communities Council Directive of November
24, 1986 (86/609/ECC).
All rats were weighed at the beginning of the study and before killing
to calculate the body weight gain during the experimental period (4 wk).
Throughout the treatment, food intake was monitored twice a week.
Bioelectrical impedance analysis was applied to body composition before
killing using a BIA 101 analyzer, modified for the rat (Akern). Fat-free
mass was calculated using the bioelectrical impedance analysis (50 kHz)
prediction equation of Ilagan et al. (25) and fat mass was determined as
the difference between body weight and fat-free mass.
After 4 wk of treatment, all rats were anesthetized by an overdose of
enflurane and killed.
Blood biochemistry. After killing, livers were excised, weighed, and
immediately frozen in liquid nitrogen and used for later experimental
procedures. Blood was collected by cardiac puncture and centrifuged at
1500 3 g; 15 min at 4C and sera were stored at 270C for later mea-
surements of aspartate amino transferase (AST), alanine amino trans-
ferase (ALT), triglycerides, and total cholesterol, by standard automated
procedures, according to the manufacturer’s protocols (AST Flex reagent
cartridge, catalog no. DF41A; ALT Flex reagent cartridge, catalog no.
DF43A; CHOL Flex reagent cartridge, catalog no. DF27; TGL Flex
reagent cartridge, catalog no. DF69A, Dade Behring). Insulin concen-
trations were measured by using a rat insulin RIA kit (Linco Research).
Liver malondialdehyde and triglycerides. The malondialdehyde
(MDA) concentrationwasmeasured as an indicator of lipid peroxidation.
Briefly, livers were homogenized in 1.15% KCl solution and processed
as previously described (26). The sample absorbance was measured by
spectrophotometry andMDAvalues were calculated by comparison with
the OD550 of standard solutions of 1,1,3,3-tetramethoxypropan 99%
malonyldialdehyde bis (dymethyl acetal) 99% (Sigma).
We measured the hepatic triglyceride concentration using a com-
mercially available kit (Triglyceride G-Test kit, Wako Pure Chemical
Industries).
Liver TNFa. Portions of liver tissues were homogenized and TNFa levels
were evaluated using a colorimetric commercial kit (Quantikine Rat
TNFa/Immunoassay, catalog no. RTA00, R&D System) according to the
manufacturer’s instructions. All TNFa determinations were performed
in duplicate serial dilutions.
Western blotting. Liver tissue (0.1 g) was disrupted by homogenization
on ice in a lysis buffer. Protein tissue lysates, mitochondrial extracts,
or nuclear and cytosolic fractions were subjected to SDS-PAGE
(8% polyacrylamide). Western blot analysis was performed as previously
described (27). In particular, the blot was probed with specific antibodies
TABLE 1 Diet composition
Std1,2 HFD3–5
g/kg %Energy g/L %Energy
Protein 185 23 42 18
Carbohydrate 990 60 28 11
Fat 55 17 80 71
1 Protein source was casein and 0.3% DL-methionine; all essential amino acids were
present at levels that met or exceeded NRC recommended levels, as previously
described (49).
2 Vitamin and mineral concentrations were in accordance with the requirements for
standard rat diets (0.52 and 0.13 g/kg, respectively) (24).
3 Protein sources were casein, 0.3% DL-methionine, and 0.5% L-cysteine.
4 Vitamin and mineral concentrations were in accordance with the requirements for
standard rat diets (2.5 and 8.75 g/L, respectively) (24).
5 Carbohydrate was 25.6 g/L maltodextrin.
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against inducible nitric oxide synthase (iNOS) (BD Biosciences Trans-
duction Laboratories; 1:1000), cyclooxygenase (COX)-2 (Cayman
Chemical; 1:1500), PPARa (Santa Cruz Biotechnology; 1:500), liver
carnitine palmitoyltransferase (LCPT) I (Santa Cruz Biotechnology;
1:2000), 3-nitrotyrosine (Upstate Biotechnology; 1:5000), IkBa (Santa
Cruz Biotechnology; 1:1000), and NF-kB p65 (Santa Cruz Biotechnol-
ogy; 1:500). Western blot for b-actin (in cell lysates) or lamin protein (in
nuclei lysates) (Sigma; 1:10,000) was performed to ensure equal sample
loading.
Metalloproteinase activity. We performed gelatin-zymography to
determine the metalloproteinase (MMP) activity of the proenzyme
forms (pro-MMP-9 and pro-MMP-2) and MMP-2 active form, as
previously described (28). The low availability of active MMP-9 in the
zymographies may have been due to its high level of instability and the
removal of active enzyme during the washing of specimens, as has been
previously suggested (29). To measure the activities of the detected
enzymes, zymograms were read using a ScanJet 3c scanner (Hewlett-
Packard). The intensities of the separate bands were analyzed using
Sigma Gel measurement software (Jandel).
Statistical analysis. All data are presented as means 6 SEM. The
statistical analysis was performed using Graph-Pad Prism (Graph-Pad
Software). The data were tested using Bartlett’s test for equality of
variance. We evaluated group differences with 1-way ANOVA followed
byNewman-Keuls post hoc comparison unless the datawere not normally
distributed, in which case evaluation was performed, using Kruskal-Wallis
test followed by Dunn’s Multiple Comparison test. A P-value of #0.05
was considered significant.
Results
Body and organ weights, liver lipids, and serum biochem-
istry. The HFD rats had greater body weight gain, fat mass,
relative liver weights, and triglyceride concentrations than rats
fed the Std diet (Table 2). Serum cholesterol and triglyceride
concentrations and AST and ALT levels, markers of liver cell
damage, also were greater in the HFD group compared with rats
receiving the Std diet.
HFD rats receiving VSL#3 had significantly lower liver
weight, triglyceride concentration, and AST serum level com-
pared with HFD-fed rats (Table 2). Food intake did not differ
between rats fed the HFD treated with vehicle (183.86 7.2 mL)
and VSL#3 (187.3 6 1.4 mL).
The rats receiving the HFD had also higher plasma insulin
concentrations (653.3 6 133.1 pmol/L) compared with rats
receiving the Std diet (241.7 6 83.4; P , 0.05), suggesting the
onset of insulin resistance. VSL#3-treated rats had significantly
lower triglyceride concentrations (Table 2) compared with rats
receiving the HFD; conversely, insulinemia was not significantly
changed (491.7 6 115.9 pmol/L).
Effect of VSL#3 on lipid peroxidation, iNOS, and S-
nitrosylation induced by HFD in liver. Peroxidation of
phospholipids generates MDA and other MDA-like aldehydes
and ketones; however, MDA is the major product that reacts
with thiobarbituric acid. HFD induced an increase in the
amount of MDA (Fig. 1A; P , 0.01 vs. Std) and VSL#3
treatment blunted this effect (P , 0.01 vs. HFD).
Because prolonged production of NO by iNOS may result in
liver damage and inflammation and considering that peroxyni-
trite is a specific marker of iNOS activity, we have determined
both the levels of nitrotyrosine (downstream reaction products
of peroxynitrite) of hepatic proteins and iNOS expression using
Western blot analysis. Protein nitrosylation and iNOS expres-
sion were increased in liver from the HFD rats compared with
rats receiving the Std diet. VSL#3 treatment completely inhibited
both alterations induced by the HFD (Fig. 1B,C).
TNFa and COX-2 modulation by VSL#3 treatment in liver
of HFD-fed rats. To evaluate the specific inflammatory response
induced by the HFD, we examined local TNFa production and
COX-2 expression in the liver. Tissue TNFa levels increased
in the liver of HFD-fed rats (P , 0.01) but were completely
inhibited by VSL#3 treatment (P , 0.01; Fig. 2A). Moreover,
a 4-wk feeding of the HFD also induced increased COX-2
expression (P , 0.01 vs. Std) that was decreased by VSL#3
treatment (Fig. 2B; P , 0.05).
Effect of VSL#3 on IkBa degradation and NF-kB p65
nuclear translocation. To investigate the mechanism by which
probiotic may attenuate the development of liver inflammation,
we evaluated by Western blot analysis the IkBa degradation and
NF-kB p65 activation in the cytosolic or nuclear extracts from
liver tissue, respectively. The basal level of IkBa was detected in
the cytosolic fraction from rats fed the Std diet, whereas the
HFD induced decreased IkBa (P, 0.05 vs. Std; Fig. 3A). VSL#3
prevented IkBa degradation (P , 0.01 vs. HFD). Moreover, the
translocation of the p65 subunit of NF-kB into the nucleus was
dramatically increased by HFD (P , 0.01 vs. Std; Fig. 3B).
VSL#3 reduced the level of NF-kB p65 in the nuclear fraction
(P , 0.01 vs. HFD).
Effect of VSL#3 treatment on PPARa and LCPT I expres-
sion. The basal level of PPARa was detected in the liver
homogenates from Std diet-fed rats. PPARa decreased in liver
from HFD rats (P , 0.05) and VSL#3 treatment prevented
the HFD-induced PPARa decrease (P , 0.01; Fig. 4A). The
expression of LCPT I, the rate-limiting enzyme in mitochondrial
fatty acid oxidation, was also measured (Fig. 4B). Its expression
in the liver of HFD-fed rats significantly increased, whereas the
treatment with VSL#3 restored its expression (Fig. 4A).
Evaluation of hepatic pro- and active MMP-2 and
proMMP-9 activity. Activation of MMP plays an important
role in the evolution of the inflammatory processes, as well as in
the pathogenesis of inflammatory disease. In particular, MMP-2
and MMP-9 are involved in liver damage. Here, we investigated
the levels of gelatinase A and B in livers obtained from rats fed a
TABLE 2 Body, liver, and adipose weights, liver triglycerides,
and serum biochemistry in rats fed Std or HFD




102.5 6 1.12b 141.7 6 3.33a 132.5 6 6.65a
Fat mass, g 24.82 6 1.09b 31.65 6 1.70a 25.95 6 1.83a,b
Relative liver weight,
g/100 g body weight
3.78 6 0.12b 4.45 6 0.11a 3.71 6 0.20b
Liver triglycerides,
mmol/g
1.13 6 0.04c 3.16 6 0.12a 2.35 6 0.11b
Serum AST, U/L 164.30 6 5.50b 253.00 6 1.08a 168.30 6 24.25b
Serum ALT, U/L 42.25 6 2.02b 59.75 6 2.87a 53.50 6 4.65b
Serum cholesterol,
mmol/L
2.49 6 0.07b 2.79 6 0.05a 2.64 6 0.02b
Serum triglycerides,
mmol/L
0.70 6 0.10b 1.1 6 0.06a 0.75 6 0.03b
1 Values are means SEM, n ¼ 6. Means without a common letter differ, P # 0.05.
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Std diet or the HFD diet alone or in combination with VSL#3.
Pro- and active MMP-2 and proMMP-9 were significantly up-
regulated in liver from HFD-fed rats. VSL#3 treatment signi-
ficantly reduced their activity (Fig. 5).
Discussion
NAFLD is a common cause of chronic liver disease both in
adults and children. The aim of the present study was to evaluate
the antioxidative and antiinflammatory effect elicited by the
probiotic mixture VSL#3 in an experimental model of NASH
induced in young rats.
We showed that a 4-wk HFD was able to induce a significant
increase of body weight gain and fat mass in young rats
compared with rats fed with a Std maintenance diet. In HFD-fed
rats, liver weight and AST serum level were elevated and these
modifications reproduce typical aspects of NASH (22,23).
In our experimental condition, the HFD evoked the mech-
anisms involved in the second hit of liver injury, in particular
the oxidative stress evidenced through the increased MDA
content and liver protein S-nitrosylation, accompanied with the
FIGURE 1 MDA content in homogenates (A), and protein nitrotyrosilated levels (B) and iNOS expression (C) in the liver from Std, HFD, or
HFD1VSL#3 groups. MDA values are means 6 SEM, n ¼ 6. The data in panel C represent relative density normalized to b-actin. Means without
a common letter differ, P , 0.01.
FIGURE 2 Liver TNFa levels (A) were obtained from Std, HFD, or
HFD1VSL#3 groups treated with VSL#3 (HFD1 VSL#3). Represen-
tative Western blot of COX-2 expression in liver homogenates from all
groups is shown (B). COX-2 modulation was revealed by densitomet-
ric analysis of all protein bands (n ¼ 6 rats from each group). The data
in panel B represent relative density normalized to b-actin. Values are
means6 SEM, n¼ 6. Means without a common letter differ, P, 0.05.
FIGURE 3 (A) Western blot analysis of IkBa levels in the cytosolic
fractions of liver lysates Std, HFD, or HFD1VSL#3 groups. The data
represent relative density normalized to b-actin. (B) Western blot
analysis of NF-kB p65 levels in the nuclear fractions of liver lysates
from all groups. A representative blot of lysates obtained is shown.
The data represent relative density normalized to lamin. Means
without a common letter differ, P , 0.05.






/jn/article-abstract/139/5/905/4670371 by guest on 17 July 2019
induction of iNOS and the strong increase of liver TNFa
content. The main targets of reactive oxygen species are the
lipids, nucleic acids, and proteins. MDA, 4-hydroxynonenal,
8-isoprostane, and 3-nitrotyrosine are produced by lipid per-
oxidation. Moreover, the level in the plasma of several oxidative
stress markers such as 4-hydroxynonenal, MDA, and thiore-
doxin increased in human NASH (30,31). Among inflammatory
cytokines, TNFa, interleukin-6, and interleukin-1b play a major
role in the pathogenesis of the disease, contributing to cause the
systemic and hepatic insulin resistance and cellular injury and
hepatic stellate cell activation (21,32–34).
Here, we found a significant decrease in PPARa and an
upregulation of COX-2 expression in livers from the HFD
group. As previously reported, in a mouse model of steatohep-
atitis, the activation of PPARa prevented the induction of
COX-2 expression (35), reducing the progression of this pathol-
ogy. The antiinflammatory role of PPARa is further supported by
the evidence that animals lacking PPARa developed steatohep-
atitis accompanied by an increased number in infiltrated lym-
phocytes and macrophages (36).
In our experimental model, the VSL#3 probiotic mixture was
found to markedly reduce the oxidative damage, protein nitro-
tyrosilation, and tissue TNFa level, interfering with the key
pathogenetic mechanisms responsible of the onset of liver damage.
We demonstrated a direct effect of VSL#3 on liver damage,
both reducing inflammatory enzymes such as iNOS and COX-2
and restoring PPARa expression reduced by the HFD.
To determine whether a HFD and probiotic treatment could
affect the expression of enzymes linked to fatty acid degrada-
tion, we also evaluated LCPT I. The rate-limiting enzyme of
long-chain fatty acid oxidation, LCPT I, ensures the first step of
long-chain fatty acid import into the mitochondrial matrix for
subsequent metabolism. Surprisingly, we found that the HFD
feeding induced a significant increase of this enzyme, despite the
downregulation of PPARa that is reported to control its gene
transcription. Actually, it has been reported that LCPT I could
also be regulated in a PPARa-independent manner (37). In
particular, the long-chain fatty acids modulate the transcription
of genes responsible of their metabolism, such as LTCP I,
increasing its expression (38,39). Therefore, we hypothesize that
the strong availability of long-chain fatty acids or change in
pancreatic hormone concentrations (glucagon or insulin) could
be responsible for the increased LCPT I expression and subse-
quent fatty acid oxidation in the mitochondria.
In our experimental conditions, VSL#3 treatment significantly
reduced serum and liver triglyceride concentrations, associated
with a reduction of fat mass, on equal food intake, sustaining the
possibility that this mixture could reduce dietary fat absorption
with a reduction of long-chain fatty acid availability and a nor-
malization of LCPT I.
The VSL#3 treatment also reduced hepatic gelatinase activity
of proMMP-2 and proMMP-9 in HFD-fed rats. Expression and
activation of MMP also play an important role in the evolution
of liver inflammatory process. Both macrophages and T cells
have been shown to produce several MMP, including MMP-1,
MMP-2, MMP-3, MMP-9, and MMP-12, and their expression
appears to be modulated by cytokines (40–42). These MMP,
which degrade the basement membrane and extracellular matrix,
are important in leukocyte migration as well as in the release of
TNFa from its membrane-bound form (43).
Previous data indicated that VSL#3 significantly ameliorates
the severity of colitis, decreasing PGE2 generation andMPO and
NOS activities (44). In humans, VSL#3 ameliorates a variety
of gastrointestinal ailments, reducing the induction and main-
tenance of remission of ulcerative colitis (45,46) and preventing
pouchitis and its relapses (14,47).
Recently, experimental and clinical data indicate an increase
of intestinal mucosa permeability with a subsequent increase
in endotoxin level into the portal circulation, initiating hepatic
necroinflammatory cascades and resulting in liver damage (46,47).
Our results strongly support the antiinflammatory and anti-
oxidative activity of VSL#3, which is responsible in the pre-
ventative effect of the early onset of NASH. Another possible
mechanism of the protective effect of VSL#3 may include the
maintenance of gut integrity. To further characterize the antiin-
flammatory mechanism of VSL#3 in HFD-induced liver damage,
we focused our attention on IkBa degradation and NF-kB
activation. The appearance of IkBa and NF-kB p65 in cytosolic or
nuclear fractions of the liver tissuewas investigated usingWestern
blot analysis. We found that the antiinflammatory effects of
VSL#3 occurred at least in part via prevention of HFD-induced
IkBa degradation. Consistent with this result, the appearance of
NF-kB p65 in the nuclear fractions was also significantly reduced
by this probiotic mix.
FIGURE 4 Representative Western blot of PPARa (A) and LCPT I
(B) expression in tissue lysates and mitochondrial extracts of liver
from Std, HFD, or HFD1VSL#3 groups for 4 wk. PPARa and LCPT I
modulation was revealed by densitometric analysis of all protein
bands. The data represent relative density normalized to b-actin.
Values are means 6 SEM, n ¼ 6. Means without a common letter
differ, P , 0.05.
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Weight loss and regular exercise are considered the first line
of treatment for NAFLD in children and adults (48), but they are
often difficult to achieve, especially in pediatric patients. Our
data demonstrating a protective effect of VSL3# on the major
key pathogenetic events of liver damage suggest the potential
clinical utility of probiotics in patients affected by this condition.
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